α-synuclein seed amplification assay positivity is associated with motor progression in the prodromal stage independent of phenoconversion

Background: α-Synuclein seed amplification assay (αSyn-SAA) has emerged as a promising biomarker for detecting underlying α-synuclein pathology and predicting phenoconversion in prodromal Parkinson's disease (PD). However, its association with longitudinal clinical progression during the prodromal stage remains unclear. We investigated whether baseline αSyn-SAA status and kinetic parameters were associated with motor and cognitive progression and subsequent phenoconversion in prodromal individuals. Methods: Clinical progression was assessed using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III motor scores, Hoehn and Yahr (H&Y) stage, and Montreal Cognitive Assessment (MoCA) scores. Linear mixed-effects models were utilized to examine the associations between baseline αSyn-SAA status, kinetic parameters, and longitudinal changes in these clinical measures. Additionally, time-to-event analyses were performed to assess the associations between SAA measurements and phenoconversion to PD or dementia with Lewy bodies. Results: We identified 2,532 participants with available baseline αSyn-SAA status in the Parkinson's Progression Markers Initiative (PPMI) prodromal cohort. This longitudinal study, which included up to 12 years of follow-up, comprised 1,714 αSyn-SAA-positive and 818 αSyn-SAA-negative individuals. Over the follow-up period, αSyn-SAA-positive participants exhibited significantly faster motor progression measured by MDS-UPDRS Part III motor score than αSyn-SAA-negative participants (0.611 vs. 0.139 points/year; P<0.001). This association persisted after excluding phenoconverters (0.430 vs. 0.202 points/year; P=0.014) and restricting follow-up to seven years (0.588 vs. 0.137 points/year; P<0.001). Among the 1,796 participants included in the time-to-event analyses, 181 phenoconversion events occurred. Baseline αSyn-SAA positivity was associated with a significantly higher hazard of phenoconversion (adjusted hazard ratio 5.72, 95% confidence interval 3.78-8.68; P<0.001), whereas kinetic parameters showed no significant associations with phenoconversion risk. Conclusions: Baseline αSyn-SAA positivity was associated with accelerated motor progression during the prodromal stage independent of phenoconversion. These findings support the potential utility of αSyn-SAA positivity as a prognostic biomarker for motor progression and phenoconversion, with implications for risk stratification and participant selection in future disease-modifying trials.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.16.26368235
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

α-synuclein seed amplification assay positivity is associated with motor progression in the prodromal stage independent of phenoconversion

Bin Xiao, Jing Han Ng, Eng‐King Tan, Prakash Kumar Manharlal et al.
5 links
medRxiv
Parkinson's Disease Mechanisms and Treatments
preprint

α-synuclein seed amplification assay positivity is associated with motor progression in the prodromal stage independent of phenoconversion

Bin Xiao, Jing Han Ng, Eng‐King Tan, Prakash Kumar Manharlal, Seyed Ehsan Saffari, Louis Tan, Mahsa Zeynali, Xiao Deng, Shermyn Neo Xiumin
preprint en

Abstract

Background: α-Synuclein seed amplification assay (αSyn-SAA) has emerged as a promising biomarker for detecting underlying α-synuclein pathology and predicting phenoconversion in prodromal Parkinson's disease (PD). However, its association with longitudinal clinical progression during the prodromal stage remains unclear. We investigated whether baseline αSyn-SAA status and kinetic parameters were associated with motor and cognitive progression and subsequent phenoconversion in prodromal individuals. Methods: Clinical progression was assessed using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III motor scores, Hoehn and Yahr (H&Y) stage, and Montreal Cognitive Assessment (MoCA) scores. Linear mixed-effects models were utilized to examine the associations between baseline αSyn-SAA status, kinetic parameters, and longitudinal changes in these clinical measures. Additionally, time-to-event analyses were performed to assess the associations between SAA measurements and phenoconversion to PD or dementia with Lewy bodies. Results: We identified 2,532 participants with available baseline αSyn-SAA status in the Parkinson's Progression Markers Initiative (PPMI) prodromal cohort. This longitudinal study, which included up to 12 years of follow-up, comprised 1,714 αSyn-SAA-positive and 818 αSyn-SAA-negative individuals. Over the follow-up period, αSyn-SAA-positive participants exhibited significantly faster motor progression measured by MDS-UPDRS Part III motor score than αSyn-SAA-negative participants (0.611 vs. 0.139 points/year; P<0.001). This association persisted after excluding phenoconverters (0.430 vs. 0.202 points/year; P=0.014) and restricting follow-up to seven years (0.588 vs. 0.137 points/year; P<0.001). Among the 1,796 participants included in the time-to-event analyses, 181 phenoconversion events occurred. Baseline αSyn-SAA positivity was associated with a significantly higher hazard of phenoconversion (adjusted hazard ratio 5.72, 95% confidence interval 3.78-8.68; P<0.001), whereas kinetic parameters showed no significant associations with phenoconversion risk. Conclusions: Baseline αSyn-SAA positivity was associated with accelerated motor progression during the prodromal stage independent of phenoconversion. These findings support the potential utility of αSyn-SAA positivity as a prognostic biomarker for motor progression and phenoconversion, with implications for risk stratification and participant selection in future disease-modifying trials.

medRxiv
National University of Singapore (SG), Duke-NUS Medical School (SG), National Neuroscience Institute (SG)
Good health and well-being
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon